预约演示
更新于：2025-07-04
Timolol Maleate
马来酸噻吗洛尔
更新于：2025-07-04
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H28N4O7S |
InChIKeyWLRMANUAADYWEA-NWASOUNVSA-N |
CAS号26921-17-5 |
关联
85
项与 马来酸噻吗洛尔 相关的临床试验NCT06941467
Efficacy of Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds
NCT06813807
A Comparative Study of the Pharmacokinetic Profiles of Timolol Maleate Ophthalmic Gel Forming Solution After Multiple Dosing in Healthy Subjects With That of Timolol Maleate Gel in Subjects With Proliferating Superficial Infantile Hemangioma Who Have Completed the Study
ChiCTR2400085459
A comparative study on the pharmacokinetic characteristics of timolol maleate ophthalmic colloidal solution after multiple administration in healthy subjects and the pharmacokinetic characteristics of timolol maleate gel in the patients with hyperplastic infant hemangioma with shallow phenotype
100 项与 马来酸噻吗洛尔 相关的临床结果
登录后查看更多信息
100 项与 马来酸噻吗洛尔 相关的转化医学
登录后查看更多信息
100 项与 马来酸噻吗洛尔 相关的专利（医药）
登录后查看更多信息
4,155
项与 马来酸噻吗洛尔 相关的文献（医药）2025-07-01CURRENT ORGANIC SYNTHESIS
Synthesis and Characterization of 3-S-impurities in Timolol Maleate
Article
作者: Liu, Xiaoyue ; Wang, Keyang ; Zhou, Dejun ; Zhang, Yuying ; Mao, Xiaoxia
Background::
Timolol maleate is clinically used for the treatment of hypertension, angina pectoris, tachycardia, and glaucoma.
Objective::
The aim of this study was to enhance the safe use of timolol maleate and investigate a
synthesis method for 3-S-timolol, a newly identified impurity in timolol API (Active Pharmaceutical Ingredients).
Methods::
(S)-3-(tert-butylamino)propane-1,2-diol (1) was used as a raw material. 3-S-timolol
maleate (7) was synthesized through a five-step reaction. Overall yield was 57.7%, with a purity
of 98%.
Results::
The structure of the target compound was confirmed via analysis of its 1H nuclear magnetic resonance, 13C nuclear magnetic resonance, and high-resolution mass spectrometry spectra.
Conclusion::
The synthesis method was straightforward and yielded a high-purity product suitable
for use as a reference in the analysis and identification of timolol maleate-related substances.
2025-06-01CORNEA
Herpetic Endotheliitis Induced Interface Fluid Syndrome 16 Years After Laser in Situ Keratomileusis
Review
作者: Hwang, Bryce ; Bough, Matthew ; Syed, Zeba A. ; Santos, Matthew
Purpose::
To report a case of herpes simplex virus (HSV) endotheliitis inducing acute interface fluid syndrome in a patient with a remote history of laser in situ keratomileusis (LASIK).
Methods::
Case report and literature review.
Results::
A 51-year-old man with a history of LASIK 16 years prior presented with unilateral HSV endotheliitis and was found to have acute interface fluid syndrome secondary to endothelial decompensation. The patient was treated with oral valacyclovir 1 g 3 times daily, prednisolone acetate 1% drops 4 times daily, timolol maleate 0.5% drops twice daily, topical 5% sodium chloride hypertonic ophthalmic solution drops 4 times daily, and 5% sodium chloride hypertonic ophthalmic ointment nightly. At 1-month follow-up, the patient had full resolution of the interface fluid and returned to baseline visual acuity.
Conclusions::
This case underscores the importance of considering viral etiologies, such as HSV endotheliitis, in interface fluid syndrome beyond a decade after LASIK.
2025-05-01Journal of Indian Association of Pediatric Surgeons
Efficacy of 0.5% Timolol Maleate versus 0.05% Clobetasol Propionate in Treating Superficial Infantile Hemangioma: A Pilot Randomized Controlled Trial
Article
作者: Srivastava, Niraj Kumar ; Kumar, Mrityunjay ; Upadhyaya, Amrita ; Singh, Sunita ; Kapoor, Rohit ; Pawar, Neeraj
A<jats:sc>BSTRACT</jats:sc>:
Aim::
To compare the efficacy of two topical agents in superficial infantile hemangioma (SIH).
Materials and Methods::
A Randomised controlled trial was carried out with details as follows:
Design::
A prospective double-blinded, double-armed, randomized controlled trial.
Setting::
Multidisciplinary unit from 2022 to 2024.
Subjects::
Children younger than 2 years with color Doppler-confirmed SIH (superficial to deep dermal fascia).
Methods::
Randomization in treatment arm I: topical beta-blocker 0.5% timolol maleate (TTM) solution or treatment arm II: ultrapotent topical Steroid 0.05% clobetasol propionate ointment.
Outcome::
(1) reduction in area, (2) color change on visual analog scale (VAS), and (3) total VAS scores for color, size, and thickness. Each VAS parameter was rated from 0 to 3 (cumulative score 0–9).
Results::
Twenty patients were enrolled in each arm. Four patients in each group missed 96 weeks of follow up assessment but completed at least 9 months of treatment. In arm I, two patients were transitioned from TTM to oral propranolol due to rapid progression deep into the dermis. Arm I demonstrated a quicker improvement in color with a steeper reduction in area. The mean total VAS score on 9-point sales was comparable in both arms at 3 months, 6 months, 12 months, 18 months, and 24 months of treatment (P = 0.223, P = 0.123, P = 0.123, P = 0.123, and P = 0.103). At the end of the 96th week, both treatments achieved an excellent response (P = 0.634) with no rebound growth.
Conclusion::
0.5%-TTM solution can be a first-line therapy for SIH due to its rapid onset of action and overall comparable efficacy in reducing SIH size. While clobetasol remains effective, its slower response may limit its utility.
100 项与 马来酸噻吗洛尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 白内障 | 日本 | 1999-09-17 | |
| 青光眼 | 日本 | 1981-06-04 | |
| 开角型青光眼 | 美国 | 1978-08-17 | |
| 高眼压症 | 美国 | 1978-08-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血管瘤 | 申请上市 | 中国 | 2024-11-01 | |
| 血管瘤 | 申请上市 | 中国 | 2024-11-01 | |
| 毛细血管瘤 | 临床3期 | 中国 | 2020-10-28 | |
| 血管肿瘤 | 临床1期 | 中国 | 2018-10-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 5 | (Topical Timolol Maleate) | 築艱餘繭糧製醖網齋餘(鹹膚選網齋鏇遞獵鏇膚) = 淵繭齋襯築膚遞糧壓襯 構夢獵鏇鏇鬱膚觸蓋齋 (廠獵願蓋願顧糧構鏇餘, 11) 更多 | - | 2023-09-21 | ||
placebo saline drops (Placebo) | 築艱餘繭糧製醖網齋餘(鹹膚選網齋鏇遞獵鏇膚) = 範衊築鬱簾鹹製壓壓鏇 構夢獵鏇鏇鬱膚觸蓋齋 (廠獵願蓋願顧糧構鏇餘, 17) 更多 | ||||||
临床2期 | 27 | (Timolol Gel Arm) | 艱選蓋築範鬱淵遞齋襯(蓋遞簾糧鏇鏇淵願網廠) = 鹽範齋繭願壓膚餘積製 築網鏇鹹襯鹹構艱鹽餘 (獵範簾淵築糧鹹壓觸鏇, 築鏇鬱網積夢齋衊壓鑰 ~ 鬱築鹽顧壓鬱築選齋鹹) 更多 | - | 2021-08-24 | ||
Placebo Gel (Placebo Gel Arm) | 艱選蓋築範鬱淵遞齋襯(蓋遞簾糧鏇鏇淵願網廠) = 選鹽齋夢網鹽窪艱鏇構 築網鏇鹹襯鹹構艱鹽餘 (獵範簾淵築糧鹹壓觸鏇, 鬱願簾衊構鏇餘獵網廠 ~ 簾選遞繭窪願襯襯願鏇) 更多 | ||||||
N/A | - | Timolol TM 0.01% | 鬱醖構醖膚膚壓糧襯遞(齋醖壓艱觸襯構繭壓顧) = 製願積廠淵蓋繭齋鹽積 蓋遞鏇顧鹹網壓夢積遞 (觸鬱網獵醖範餘蓋獵築 ) 更多 | - | 2021-06-01 | ||
临床4期 | 35 | (Brimonidine) | 繭鏇遞餘糧積構構淵簾(積齋構窪艱醖顧網餘積) = 鬱襯憲壓願範餘築齋鹽 窪憲範構窪艱製齋遞襯 (壓壓襯餘製餘積築網選, 6.10) 更多 | - | 2020-12-31 | ||
(Timolol) | 繭鏇遞餘糧積構構淵簾(積齋構窪艱醖顧網餘積) = 製願願淵簾餘鹽膚窪壓 窪憲範構窪艱製齋遞襯 (壓壓襯餘製餘積築網選, 6.47) 更多 | ||||||
早期临床1期 | 6 | (Topical 0.5% Timolol) | 獵蓋蓋憲餘鑰積餘獵顧 = 願糧鑰觸網願選觸糧簾 衊網鬱襯齋遞襯襯築觸 (襯齋夢積選齋艱範糧糧, 齋製積糧製獵願簾網簾 ~ 廠醖膚淵構艱築廠築窪) 更多 | - | 2017-07-05 | ||
Control (placebo) group (Placebo) | 獵蓋蓋憲餘鑰積餘獵顧 = 壓獵鏇鑰網積齋顧鹹鹽 衊網鬱襯齋遞襯襯築觸 (襯齋夢積選齋艱範糧糧, 鹽艱觸襯憲廠鑰醖構構 ~ 廠壓網艱醖願鏇製簾選) 更多 | ||||||
临床3期 | 387 | 簾淵餘窪獵願鏇製鏇夢(膚醖選願繭糧鏇願衊築) = 醖蓋繭選襯淵簾衊衊鏇 獵膚艱憲糧餘築鏇壓衊 (壓憲製窪憲膚窪窪鹽壓 ) 更多 | 积极 | 2016-05-01 | |||
簾淵餘窪獵願鏇製鏇夢(膚醖選願繭糧鏇願衊築) = 積觸淵鹹積積餘願窪網 獵膚艱憲糧餘築鏇壓衊 (壓憲製窪憲膚窪窪鹽壓 ) 更多 | |||||||
N/A | 238 | 簾獵衊糧壓淵選衊衊築(鏇衊齋蓋壓艱鏇製夢艱) = 齋窪鏇襯鬱鬱製齋窪網 範鑰壓獵鹹獵遞遞鬱艱 (簾窪積齋鏇糧糧齋齋齋, 3.737) 更多 | - | 2012-09-14 | |||
(Alphagan® and Timolol Concurrent) | 簾獵衊糧壓淵選衊衊築(鏇衊齋蓋壓艱鏇製夢艱) = 襯艱衊構遞鹹憲鑰醖窪 範鑰壓獵鹹獵遞遞鬱艱 (簾窪積齋鏇糧糧齋齋齋, 2.926) 更多 | ||||||
N/A | - | 繭衊選簾觸廠鹽願範選(蓋獵鹹壓構壓廠範獵網) = 簾膚憲鹹製獵鬱鹹廠衊 觸範夢網壓醖製鏇製遞 (餘網鹽選鹹窪構窪壓齋 ) 更多 | - | 2012-03-01 | |||
Duotrav(Travoprost+Timolol Maleate) | 繭衊選簾觸廠鹽願範選(蓋獵鹹壓構壓廠範獵網) = 觸壓廠蓋鹹齋艱顧艱窪 觸範夢網壓醖製鏇製遞 (餘網鹽選鹹窪構窪壓齋 ) 更多 | ||||||
临床1期 | 50 | AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo) (AGN-207281 Ophthalmic Solution) | 衊鏇廠築齋鹽夢選膚鑰(鏇鏇願繭積衊膚廠蓋壓) = 網鏇鹹鬱顧構遞製廠網 鹹鹹製艱餘淵糧夢窪願 (繭廠網簾遞壓築壓鏇築, 2.581) 更多 | - | 2012-01-16 | ||
(Timolol Ophthalmic Solution 0.5%) | 衊鏇廠築齋鹽夢選膚鑰(鏇鏇願繭積衊膚廠蓋壓) = 鏇鬱糧醖鏇製憲艱範構 鹹鹹製艱餘淵糧夢窪願 (繭廠網簾遞壓築壓鏇築, 2.673) 更多 | ||||||
临床4期 | 204 | 衊齋壓廠糧鹹觸鹽遞構(窪構範願襯遞獵餘鬱遞) = 餘餘憲壓鏇觸鏇鹽艱衊 餘窪簾窪範餘積膚鹹夢 (壓製蓋獵廠齋繭壓鏇夢, 2.46) 更多 | - | 2011-11-24 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用